US 8759302
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
granted A61KA61K38/02A61K38/07
Quick answer
US patent 8759302 (Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K38/02, A61K38/07, A61K38/16, A61P